Claris Lifesciences Limited(BSE:533288 NSE:) ,Company Snapshot, Recent Developments, Latest News, Financials, Price Charts, Ratios, Contact Information

Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals

Home

News Centre

IPO

Markets	Companies	Research	Industries	E-Mail Page

my Last 5 Scrips
Company	BSE Price(Rs)	% Chg
Tata Mot	297.10	0.82
Tata Stl	284.70	2.89
Hindalco	101.50	0.49
I T C Lt	330.15	0.53
Sterlite	83.05	0.97
Clear All	Clear Last

NSE Live
Nifty Live Prices Live Quotes Top Gainers/Losers Top 10 Turnover No Delivery Stocks

BSE Live
BSE30 Live Prices Live Quotes Top Gainers/Losers Top 10 Turnover No Delivery Stocks

Market Pulse
Leaders Laggards FII Activity Mutual Fund Activity Meetings

Results Watch
Results Calendar Results Announced

IPO Watch

Company
Snapshots Quotes Charts Financials Recent News Broker Research Meetings Research Tutorial Discussion Forum

Research
Research Reports

Sector Watch

Economy Watch

Snapshot-Claris Lifesciences Limited

Claris Lifesciences Limited

Sector:Pharmaceuticals Pharmaceuticals - Pharmaceuticals - Others
BSE:533288	NSE:NA	Bloomberg:CLAR@IN	Reuters:CLAI.BO
Market Lot: 1	Face Value: 10	ISIN Demat: INE562G01018

Quotes	Snapshot	Charts	Financials	Research	Recent News
Peer Group	AGM/AM	MF Holding	Discussion Forum	BSE/NSE Notices	BSE/NSE Deals

Recent Developments
06-JUN-13 Claris Lifesciences announced today that it has received an Abbreviated New Drug Application (ANDA) approval for Levofloxacin Injection; having strength of 25mg/ ml in 20 ml vials in the United States. 07-MAY-13 India Ratings & Research (Ind-Ra) has assigned Claris Lifesciences`s (Claris) additional Rs 1.2 billion term loan a Long Term `` A-` rating and placed it on Rating Watch Positive (RWP). 02-MAY-13 Claris Lifesciences announce... More..
Business Profile	Future Plans

One To One

Latest News

Claris Lifesciences gets ANDA nod for Levofloxacin in US -IRIS 06-Jun-13

Brief Financials (in Rs. Mn.)

Period ending (months)
Net sales
Other Income
Total Income
Cost of goods sold
OPBDIT
PAT
Gross Block
Equity capital
EPS (Rs.)
DPS (Rs.)
BV (Rs.)
P/E range (x)
Debt / Equity (x)
Operating margin (% of OI)
Net margin (% of OI)